Are you interested in learning about or participating in a hepatitis C virus (HCV) clinical research study? If so, choosing to participate in a clinical trial is an important personal decision. To learn what a clinical trial is, the pros and cons of participating, who is eligible to participate, and many more commonly asked questions CLICK HERE This will provide you with detailed information about clinical trials. In addition, it is often helpful to talk to a physician, family members, or friends about deciding to join a trial. After identifying some trial options, the next step is to contact the study research staff and ask questions about specific trials. To find a clinical trial in your area CLICK HERE
Source
Learning About Clinical Trials
Summary of investigational Hepatitis C drugs presented at the 2011 EASL Conference
Hepatitis C New Drug Pipeline; New drugs in development for the treatment of hepatitis C
http://www.hcvdrugs.com/
Quick Reference guide to better understand the various “Phases” of clinical trials:
PHASE I TRIALS: Initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
PHASE II TRIALS: Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks.
PHASE III TRIALS: Expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling.
http://www.clinicaltrials.gov/
1
Recruiting
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin
Condition:
Hepatitis C Virus
Interventions:
Drug: BMS-650032; Drug: Placebo; Drug: Peginterferon Alfa-2a; Drug: Ribavirin
2
Recruiting
GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus
Condition:
Hepatitis C, Chronic
Interventions:
Drug: GS-5885; Drug: GS-9451; Biological: peginterferon alfa-2a; Drug: ribavirin tablet
3
Recruiting
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
Condition:
Hepatitis C, Chronic
Interventions:
Drug: GS-5885 placebo; Drug: GS-5885 tablet; Drug: GS-9451 placebo; Drug: GS-9451 tablet; Drug: Tegobuvir placebo; Drug: Tegobuvir; Biological: peginterferon alfa-2a; Drug: ribavirin tablet
4
Recruiting
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Condition:
Hepatitis C, Chronic
Interventions:
Drug: Tegobuvir (GS-9190); Drug: GS-9451; Biological: Pegasys®; Drug: Copegus®; Drug: Tegobuvir placebo; Drug: GS-9451 placebo
5
Not yet recruiting
GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
Condition:
Chronic Hepatitis C
Interventions:
Drug: GS-5885, GS-9451, PEG , RBV; Drug: PEG, RBV
6
Recruiting
GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
Condition:
Hepatitis C, Chronic
Interventions:
Drug: GS-5885; Drug: Tegobuvir; Drug: GS-9451; Drug: ribavirin tablet
7
Recruiting
Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia
Conditions:
Hepatitis C Infection; Thrombocytopenia
Interventions:
Biological: romiplostim; Drug: ribavirin; Other: placebo; Biological: PEG-interferon alfa-2a; Other: laboratory biomarker analysis
8
Recruiting
A Randomized, Active-Control Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic Hepatitis C Virus Genotype 1 Infection
Condition:
Hepatitis C
Interventions:
Drug: Bavituximab; Drug: Pegylated interferon (PEG-IFN)
9
Recruiting
CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects
Condition:
Chronic Hepatitis C
Interventions:
Drug: ChronVac-C + SOC; Drug: SOC
10
Recruiting
Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
Condition:
Hepatitis C, Chronic
Interventions:
Drug: PEG-rIL-29; Drug: Peginterferon alfa-2a; Drug: Ribavirin
11
Recruiting
Study of SCY-635, Pegasys and Copegus in Hepatitis C
Condition:
Hepatitis C Infection
Interventions:
Drug: Placebo; Drug: SCY-635; Drug: peginterferon alfa 2a; Drug: Ribavirin
12
Recruiting
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Condition:
Hepatitis C
Interventions:
Biological: Pegylated Interferon Lambda (pegIFNλ); Drug: BMS-790052 (NS5A Inhibitor); Drug: Ribavirin (RBV); Drug: BMS-650032 (NS3 Protease Inhibitor); Biological: Pegylated Interferon Alfa-2a (pegIFNα-2a); Drug: Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor); Drug: Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor); Drug: Placebo for Ribavirin (RBV)
13
Recruiting
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects
Conditions:
Hepatitis; Hepatitis C
Interventions:
Drug: Filibuvir; Drug: Placebo
14
Recruiting
Ph IIA Study (SOC +/- NS5B)
Condition:
Hepatitis C Virus
Interventions:
Drug: BMS-791325; Drug: Placebo; Drug: Peg-interferon alfa-2a; Drug: Ribavirin
15
Recruiting
Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection
Condition:
Genotype 1 Chronic Hepatitis C
Interventions:
Drug: GI-5005; Drug: Pegylated Interferon and Ribavirin
16
Recruiting
S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate in Preventing Liver Cancer in Patients With Chronic Hepatitis C Infection
Conditions:
Infection; Liver Cancer
Interventions:
Drug: S-adenosyl-L-methionine disulfate p-toluene-sulfonate; Other: placebo
17
Recruiting
Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype-1 Patients With Chronic HCV Infection
Condition:
Hepatitis C
Interventions:
Drug: Placebo; Drug: ANA598; Drug: Ribavirin; Drug: Pegylated Interferon
18
Recruiting
Efficacy and Safety of DEB025 Combined With Peg-IFN Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Relapsers and Non-responders
Condition:
Hepatitis C Chronic
Interventions:
Drug: DEB025 600 mg QD + SOC; Drug: DEB025 800 mg QD; Drug: placebo + SOC; Drug: DEB025 400 mg BID + SOC
19
Recruiting
Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes
Condition:
Hepatitis C, Chronic
Interventions:
Drug: Placebo; Drug: PF-04136309
20
Recruiting
Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects
Condition:
Hepatitis C
Interventions:
Drug: miravirsen; Drug: saline
21
Recruiting
Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced Fibrosis
Condition:
Chronic Hepatitis C
Interventions:
Drug: Ribavirin; Drug: Colchicine
22
Recruiting
A Study of Vaniprevir (MK-7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028 AM4)
Condition:
Hepatitis C, Chronic
Interventions:
Drug: Vaniprevir (600 mg b.i.d.); Drug: Vaniprevir (300 mg b.i.d.); Drug: Pegylated interferon (Peg-IFN); Drug: Ribavirin (RBV)
23
Recruiting
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis
Condition:
Chronic Hepatitis C
Interventions:
Drug: Fuzheng Huayu; Drug: Placebo
24
Recruiting
Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance
Condition:
Hepatitis C
Intervention:
Drug: thalidomide
25
Not yet recruiting
Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
Condition:
Thrombocytopenia
Intervention:
Drug: E5501 (previously known as AKR-501 monomaleate)
26
Recruiting
Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C
Conditions:
HCV Infection; Liver Transplantation
Interventions:
Biological: MBL-HCV1; Other: 0.9% Sodium chloride Placebo
27
Recruiting
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
Conditions:
Hepatitis C; Hepatitis C, Chronic
Interventions:
Procedure: Continuous maintenance immunosuppressive therapy; Procedure: Immunosuppression withdrawal; Procedure: Liver transplant
28
Recruiting
Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients
Condition:
Hepatitis C
Intervention:
Drug: ribavirin pre-treatment
29
Recruiting
Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4
Conditions:
Liver Cirrhosis; Hepatitis C Virus; HIV Infection
Intervention:
Drug: Pegylated interferon alfa-2a and Ribavirin
30
Recruiting
Telaprevir In HIV-HCV Coinfected Patients Who Had Previously Failed A Peginterferon-Ribavirin Regimen
Conditions:
Hepatitis C, Chronic; HIV Infection
Interventions:
Drug: Telaprevir; Biological: peginterferon alfa-2a; Drug: Ribavirin
31
Recruiting
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
Condition:
Chronic Hepatitis C
Intervention:
Drug: SCV-07
32
Not yet recruiting
TMC435-TiDP16-C213 - Phase III, Open-Label Roll-Over Trial of TMC435 + Peginterferon Alfa-2A and Ribavirin for Patients Who Participated in Control Group of a TMC435 Study
Condition:
Hepatitis C
Intervention:
Drug: TMC435
33
Recruiting
A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C
Conditions:
Chronic Hepatitis C Infection; Genotype 1
Interventions:
Drug: recombinant variant of interferon-alpha 2b; Drug: Peginterferon alfa-2a
34
Recruiting
A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C
Conditions:
Chronic Hepatitis C Virus Infection; Genotype 1; Treatment-Experienced Patients; Relapses
Interventions:
Drug: Interferon α-5; Drug: Interferon-α5 plus Interferon-α 2b; Drug: Interferon α-2b (INTRON® A)
35
Recruiting
A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1
Condition:
Chronic Hepatitis C
Interventions:
Drug: CF 102; Drug: Placebo
36
Not yet recruiting
Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.
Condition:
Chronic Hepatitis C
Intervention:
Biological: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin
37
Recruiting
Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis
Conditions:
Acute Hepatitis A; Acute Hepatitis B; Acute Hepatitis C; Acute Hepatitis E; Acute EBV Hepatitis; Acute CMV Hepatitis
Interventions:
Dietary Supplement: Silymarin; Other: Lactose monohydrate
38
Recruiting
Efficacy and Safety of DEB025 Alone or Combined With Either Ribavirin or Peg-IFN α2a in Chronic Hepatitis C Genotype 2 and 3 naïve Patients
Conditions:
Hepatitis C; Chronic Pain
Interventions:
Drug: DEB025 1000 mg QD; Drug: DEB025 600 mg QD + RBV 400 mg BID; Drug: DEB025 800 mg QD + RBV 400 mg BID; Drug: DEB025 600 mg QD + peg-IFNα2a once weekly; Drug: SOC (peg-IFNα2a once weekly + RBV 400 mg BID)
39
Recruiting
Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients
Condition:
Hepatitis C
Interventions:
Drug: Placebo; Drug: Nitazoxanide
40
Recruiting
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
Condition:
Chronic Hepatitis C Virus Infection
Interventions:
Drug: telaprevir; Drug: VX-222; Drug: ribavirin; Biological: peginterferon-alfa-2a
41
Recruiting
Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone
Condition:
Hepatitis C
Intervention:
Drug: Interleukin-7
42
Recruiting
Safety, Tolerability and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in HCV Positive Subjects
Condition:
Hepatitis C
Interventions:
Drug: ACH-0141625; Drug: Placebo; Drug: Pegylated Interferon alpha-2a; Drug: ribavirin
43
Recruiting
Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C
Conditions:
Self Efficacy; Hepatitis C
Intervention:
Drug: pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg
44
Recruiting
Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
Conditions:
Hepatitis C Virus (HCV); Chronic Hepatitis C
Interventions:
Drug: ABT-267; Drug: Peginterferon alpha-2a (pegIFN); Drug: Ribavirin (RBV); Drug: Placebo
45
Recruiting
Ribavirin Dose Optimization for the Treatment of Hepatitis C
Condition:
Chronic Hepatitis C
Intervention:
Drug: Peg-interféron alpha-2a (Pegasys) and Ribavirin (RBV)
46
Recruiting
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care
Condition:
Chronic Hepatitis C
Interventions:
Drug: BMS-790052; Drug: BMS-650032; Drug: Pegylated-interferon alfa-2a; Drug: Ribavirin
47
Recruiting
Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders
Condition:
Hepatitis C
Intervention:
Drug: Silibinin
48
Recruiting
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003)
Condition:
Hepatitis C, Chronic
Interventions:
Drug: MK-5172; Drug: Boceprevir; Drug: Placebo for MK-5172; Drug: Placebo for Boceprevir; Drug: Peg-interferon alfa-2b; Drug: Ribavirin
49
Recruiting
A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C
Condition:
Hepatitis C, Chronic
Interventions:
Drug: danoprevir; Drug: ritonavir; Drug: RO5024048; Drug: Copegus; Drug: Pegasys
50
Recruiting
Study Comparing Reduction and Viral Safety of IFN Alfa-2b XL + Ribavirin Versus PEG IFN Alfa-2b + Ribavirin in Patients With Chronic Hepatitis C Genotype 1
Condition:
Chronic Hepatitis C
Interventions:
Drug: IFN alfa-2b XL 27 MUI + Ribavirin; Drug: IFN alfa-2b XL 36 MUI + Ribavirin; Drug: IFN peg alfa-2b 1.5 µg/kg + Ribavirin
51
Recruiting
Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Not Been Treated With Standard of Care
Condition:
Chronic Hepatitis C
Interventions:
Drug: PSI-7977; Drug: BMS-790052; Drug: Ribavirin
52
Recruiting
Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)
Condition:
Hepatitis C
Intervention:
Drug: Telaprevir
53
Recruiting
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
Condition:
Hepatitis C, Chronic
Interventions:
Drug: danoprevir; Drug: ritonavir; Drug: peginterferon alfa-2a [Pegasys]; Drug: Copegus; Drug: daneprovir
54
Recruiting
Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3
Condition:
Chronic Hepatitis C Infection
Intervention:
Drug: PSI-7977 with and without ribavirin (RBV) and/or Pegylated Interferon (PEG-IFN)
55
Recruiting
High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
Condition:
Chronic Hepatitis C
Interventions:
Drug: Peginterferon; Drug: Ribavirin
56
Recruiting
PSI-7977 With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6
Condition:
Hepatitis C, Chronic
Intervention:
Drug: PSI-7977 with PEG/RBV
57
Recruiting
Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C
Conditions:
Chronic Hepatitis C; Oxidative Stress
Interventions:
Dietary Supplement: silymarin; Dietary Supplement: green tea extract (EGCG)
58
Recruiting
Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection
Condition:
Recurrent Hepatitis C
Interventions:
Drug: Everolimus; Drug: standard treatment
59
Recruiting
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
Condition:
Hepatitis C Virus (HCV) Infection
Interventions:
Drug: CTS-1027; Drug: pegylated interferon; Drug: Ribavirin; Drug: Placebo
60
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Condition:
Chronic Hepatitis C, Hepatitis C, Hepatitis C Virus (HCV)
Interventions:
Drug: ABT-450/r; Drug: ABT-333; Drug: ribavirin
61
Recruiting
Study the Relationship Between Obesity and Hepatitis C Replication
Condition:
Hepatitis C
Intervention:
Drug: Pioglitazone, Prednisone
62
Recruiting
A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures
Conditions:
HIV; HCV; HCV Genotype 1
Intervention:
Drug: Nitazoxanide
63
Recruiting
A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients
Condition:
Hepatitis C
Interventions:
Drug: LCQ908; Drug: Placebo
64
Recruiting
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
Condition:
Chronic Hepatitis C
Intervention:
Drug: CT-011
65
Recruiting
Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Nonresponders to Antiviral Therapy
Condition:
Chronic Hepatitis C
Intervention:
Drug: vitamin D
66
Recruiting
Safety and Efficacy Study in Hepatitis C Patients With PHN121
Condition:
Hepatitis C Virus Infection
Intervention:
Drug: PHN121
67
Not yet recruiting
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
Condition:
Hepatitis C, Chronic
Intervention:
Drug: IDX184
68
Recruiting
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
Conditions:
Hepatic Encephalopathy; Hepatitis C; Liver Cirrhosis
Intervention:
Drug: Rifaximin (drug)
69
Recruiting
A Study on The Combination of RO5024048 And Ritonavir-Boosted Danoprevir With And Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)
Condition:
Hepatitis C, Chronic
Interventions:
Drug: RO5024048; Drug: danoprevir; Drug: ritonavir; Drug: ribavirin [Copegus]; Drug: Copegus placebo
70
Recruiting
Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)
Condition:
Hepatitis C
Intervention:
Drug: Interleukin-7
71
Recruiting
Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin
Conditions:
HCV Coinfection; HIV-1 Infection
Intervention:
Drug: Boceprevir, Peg-interferon alfa 2b and Ribavirin
72
Recruiting
Brief Intervention for Drug Misuse in the Emergency Department
Conditions:
Substance Abuse Detection; Acquired Immunodeficiency Syndrome; Hepatitis B; Hepatitis C; Brief Intervention; HIV Infections
Intervention:
Behavioral: Brief motivational intervention
73
Not yet recruiting
TMC435HPC3002 - 3-Year Follow up of Patients After Administration of TMC435 for the Treatment of Chronic Hepatitis C.
Condition:
Hepatitis C
Intervention:
Other: Blood samples
74
Recruiting
Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults
Conditions:
Neurofibromatosis Type 1; Plexiform Neurofibroma
Intervention:
Drug: PEG-interferon alfa-2b
75
Recruiting
Study of PEG-Intron for Plexiform Neurofibromas
Condition:
Plexiform Neurofibroma
Intervention:
Drug: PEG-Intron
76
Recruiting
Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Condition:
HIV Infection
Intervention:
Drug: Interferon Alpha 2b
77
Recruiting
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia
Conditions:
Anemia, Aplastic; Anemia, Hypoplastic; Thrombocytopenia
Interventions:
Drug: Eltrombopag (Promacta); Drug: Eltrombopag
78
Recruiting
ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV
Condition:
Hepatitis
Intervention:
Drug: Peg-interféron alpha 2a + ribavirine
79
Recruiting
TMC435-TiDP16-C216 - Phase III Trial of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients
Condition:
Hepatitis C
Interventions:
Drug: Placebo; Drug: TMC435
80
Recruiting
A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients
Condition:
Hepatitis C, Chronic
Interventions:
Drug: TMC435; Drug: Placebo
81
Recruiting
A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Failed to Respond to Previous IFN-based Therapy
Condition:
Hepatitis C, Chronic
Intervention:
Drug: TMC435
82
Recruiting
TMC435HPC3007 - Phase III Trial of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
Condition:
Hepatitis C
Interventions:
Drug: TMC435; Drug: Placebo
83
Recruiting
TMC435-TiDP16-C208 - Phase III Trial of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients
Condition:
Hepatitis C
Interventions:
Drug: TMC435; Drug: Placebo
84
Recruiting
Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
Conditions:
HIV Infection; Liver Failure; Liver Transplantation
Intervention:
Drug: Raltegravir potassium
85
Recruiting
PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)
Condition:
Chronic Hepatitis C
Intervention:
Drug: Peginterferon alfa-2a and Ribavirin
86
Not yet recruiting
Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)
Condition:
Hepatitis C, Chronic
Interventions:
Drug: vaniprevir; Drug: Placebo to vaniprevir; Biological: peg-IFN alfa-2b; Drug: ribavirin
87
Recruiting
Study of a Novel Therapeutic Vaccine for Hepatitis C Virus
Condition:
Hepatitis C
Interventions:
Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut ; Ad6NSmut
88
Recruiting
A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy
Condition:
Hepatitis C, Chronic
Intervention:
Drug: TMC435
89
Recruiting
A Study of TMC435 in Genotype 1, Hepatitis C-Iinfected Patients (Treatment-Naive or Interferon-Based Treatment Experienced)
Condition:
Hepatitis C, Chronic
Intervention:
Drug: TMC435
90
Not yet recruiting
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
Condition:
Hepatitis C, Chronic
Interventions:
Drug: Pegylated interferon alfa 2b; Drug: Ribavirin
91
Recruiting
Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load
Condition:
Hepatitis C
Interventions:
Drug: DFPP + Peg-IFN + RBV; Drug: Peg-IFN + RBV
92
Recruiting
Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies
Condition:
Hemoglobinopathies
Intervention:
Drug: PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
93
Recruiting
Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Dialysis Patients With Chronic Hepatitis C
Condition:
Chronic Hepatitis C
Interventions:
Drug: Pegylated interferon alfa-2a plus low dose ribavirin; Drug: Pegylated interferon alfa
94
Recruiting
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.
Condition:
Hepatitis C, Chronic
Intervention:
Drug: peginterferon alfa-2a [Pegasys]
95
Recruiting
Study of a New MVA Vaccine for Hepatitis C Virus
Condition:
Hepatitis C
Interventions:
Biological: MVA-NSmut; Biological: AdCh3NSmut; MVA-NSmut; Biological: AdCh3NSmut ; MVA-NSmut
96
Recruiting
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Condition:
Hepatitis C, Chronic
Interventions:
Drug: BI 207127; Drug: BI 201335; Drug: RBV
97
Recruiting
TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.
Conditions:
Hepatitis C; HIV
Interventions:
Drug: ETR/telaprevir; Drug: TMC278/telaprevir; Drug: telaprevir/ETR; Drug: telaprevir/TMC278
98
Recruiting
Efficacy and Safety Study of DEB025/Alisporivir Combined to Standard Therapy (Peg-IFN and Ribavirin) in Chronic Hepatitis C Genotype 1 naïve Patients
Condition:
Hepatitis C, Chronic
Interventions:
Drug: Standard of Care (SOC: Peg-IFN once weekly + Ribavirin BID) + DEB025; Drug: SOC + DEB025 400 mg; Drug: SOC + DEB025; Drug: Placebo + SOC for 48 weeks
99
Recruiting
Efficacy and Safety of BI201335 in Combination With Pegylated Interferon Alpha and Ribavirin in Treatment Naive Genotype 1 Hepatitis C Infected Patients (Double Blind, Randomized, Placebo Controlled, Phase III)
Condition:
Hepatitis C
Interventions:
Drug: BI201335; Drug: PegIFN/RBV
100
Recruiting
Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR
Condition:
Chronic Hepatitis C
Intervention:
Drug: Pegylated interferon alfa-2a + ribavirin
101
Recruiting
Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C
Conditions:
Hepatitis C Virus Infection; Infection; Herpesvirus 2, Human
Intervention:
Drug: Valacyclovir
102
Recruiting
A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
Condition:
Hepatitis C, Chronic
Interventions:
Drug: peginterferon alfa-2a [Pegasys]; Drug: Copegus
103
Not yet recruiting
A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)
Condition:
Hepatitis C, Chronic
Interventions:
Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]
104
Not yet recruiting
A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy
Condition:
Hepatitis C, Chronic
Interventions:
Drug: peginterferon alfa 2a [Pegasys]; Drug: peginterferon alfa-2a [Pegasys]
105
Recruiting
Open Label Study to Evaluate the Safety, Efficacy, Viral Kinetics, Genetic, Epigenetic, and Proteomic Expression of Weekly Peginterferon Alpha 2a and Ribavirin Therapy for Chronic Hepatitis C in Latino Subjects With and Without HIV Co-infection
Conditions:
Hepatitis C; HIV
Intervention:
Drug: Pegylated interferon with ribavirin
106
Not yet recruiting
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Condition:
Hepatitis C, Chronic
Interventions:
Drug: peginterferon alfa-2a [Pegasys]; Drug: COPEGUS
107
Recruiting
100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)
Conditions:
Sustained Virologic Response; IL28B Polymorphism
Interventions:
Drug: peginterferon alfa 2a (pegasys); Drug: peginterferon alfa-2a (pegasys)
108
Recruiting
A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1
Condition:
Hepatitis C, Chronic
Interventions:
Drug: danoprevir; Drug: ritonavir; Drug: placebo; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin
109
Not yet recruiting
BMS-790052 Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
Condition:
Hepatitis C
Interventions:
Drug: BMS-790052 (NS5A Replication Complex Inhibitor); Drug: Peg-Interferon Alfa-2a; Drug: Ribavirin
110
Recruiting
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
Condition:
Hepatitis C, Chronic
Interventions:
Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]
111
Recruiting
A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C
Condition:
Hepatitis C, Chronic
Interventions:
Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin
112
Recruiting
Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients
Condition:
Hepatitis C, Chronic
Interventions:
Drug: pegylated interferon alpha-2b; Drug: Ribavirin; Drug: pegylated Interferon alpha-2b
113
Recruiting
Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy
Condition:
Hepatitis C
Intervention:
Drug: Pegylated interferon-alfa-2b and ribavirin
114
Recruiting
EXtended Therapy in Hepatitis C Genotype 3 Infected Patients
Condition:
Chronic Hepatitis C
Intervention:
Drug: Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)
115
Recruiting
The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin
Condition:
Chronic Hepatitis C
Interventions:
Drug: Pioglitazone; Drug: Acarbose; Drug: Metformin
116
Recruiting
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma
Conditions:
Chronic Hepatitis C; Neoplasms
Intervention:
Drug: Peginterferon alfa-2a plus ribavirin
117
Recruiting
High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4
Condition:
Chronic Hepatitis C Genotype One or Four
Intervention:
Drug: ribavirin
118
Not yet recruiting
Treatment of Recently Acquired Hepatitis C Virus Infection
Condition:
Acute Hepatitis C
Interventions:
Drug: Peginterferon alfa-2a; Drug: Ribavirin
119
Recruiting
Low-Dose Peg-Interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
Condition:
Hepatitis C, Chronic
Intervention:
Drug: interferon-alfa-2b and ribavirin
120
Not yet recruiting
A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C
Condition:
Healthy Volunteer, Hepatitis C
Interventions:
Drug: RO5428029; Drug: placebo
121
Recruiting
An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Condition:
Hepatitis C
Intervention:
122
Recruiting
Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1
Condition:
Hepatitis C
Interventions:
Drug: Ribavirin "loading" dose given; Drug: "Priming" dose of ribavirin given; Drug: Group C ("Standard-of-Care")
123
Recruiting
TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients
Condition:
Hepatitis C
Interventions:
Drug: Placebo; Drug: TMC647055; Drug: TMC435
124
Recruiting
Follow Up of Patients Chronic Hepatitis B (CHB) Treated With Sebivo Using the 13C Methacetin Breath Test
Condition:
Chronic Hepatitis B
Intervention:
Device: 13C Methacetin Breath Test (BreathID)
125
Recruiting
Pioglitazone Versus Placebo in Association With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Patients With Insulin Resistance
Conditions:
Chronic Hepatitis C; Insulin Resistance
Interventions:
Drug: Pioglitazone; Drug: Placebo
126
Recruiting
A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients
Condition:
Chronic Hepatitis C
Interventions:
Drug: Peginterferon alfa2a; Drug: Ribavirin
127
Recruiting
Quality of Life in Chronic Hepatitis C (Study P05278)
Conditions:
Hepatitis C, Chronic; Genotype 1; HCV-1
Interventions:
Biological: Peginterferon alfa-2b; Drug: Ribavirin
128
Recruiting
Injecting Drug Use Community Intervention Trial
Conditions:
HIV; Hepatitis C; Syphilis; HSV-2; HIV Infections
Intervention:
Behavioral: Intervention
129
Recruiting
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Condition:
Hepatitis C, Chronic
Intervention:
Drug: GS-6620
130
Recruiting
Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance Imaging
Conditions:
Iron Overload; Metabolic Syndrome X; Hepatitis B; Hepatitis C; Alcohol Abuse
Intervention:
Device: Magnetic resonance imaging multiecho gradient-echo sequence
131
Not yet recruiting
Fluvastatin, Simvastatin to Improve Interferon Sensitivity
Condition:
Chronic Hepatitis C
Intervention:
Drug: statin
132
Recruiting
A Open-label Study to Evaluate the Relative Bioavailability of IDX184 and Food Effect in Healthy Male Subjects
Condition:
Hepatitis C
Intervention:
Drug: IDX184
133
Not yet recruiting
Safety of Raltegravir When Given as Part of HIV Therapy in HIV/HCV Coinfected Individuals
Condition:
HIV/ Hepatitis C Co-Infection
Interventions:
Drug: Raltegravir (Isentress); Drug: Efavirenz (Sustiva)
134
Recruiting
Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C
Condition:
Hepatitis C
Intervention:
135
Recruiting
The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis
Condition:
Hepatitis
Interventions:
Drug: Pioglitazone; Drug: placebo
136
Recruiting
Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients
Conditions:
Obesity; Insulin Resistance; Metabolic Syndrome; Hepatitis C
Interventions:
Drug: Orlistat; Behavioral: Dietary and Lifestyle modification educational sessions
137
Recruiting
Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B
Condition:
Chronic Hepatitis B
Interventions:
Drug: Pegasys plus Entecavir; Drug: Entecavir
138
Recruiting
Pilot Study of Hepatitis C Virus Entry Inhibitor (ITX 5061) in Liver Transplant Recipients
Conditions:
Hepatitis C; Evidence of Liver Transplantation
Intervention:
Drug: ITX 5061
139
Recruiting
Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds
Conditions:
HIV Infection; Hepatitis C Virus Infection
Interventions:
Drug: Anti-HIV Agents; Drug: raltegravir; Drug: Emtricitabine and tenofovir disoproxil fumarate
140
Recruiting
Baclofen to Reduce Alcohol Use in Veterans With HCV
Conditions:
Hepatitis C; Alcohol Use Disorders
Interventions:
Drug: baclofen; Drug: placebo
141
Recruiting
Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)
Condition:
Hepatitis C
Interventions:
Drug: MK-6325; Drug: Placebo to MK-6325
142
Recruiting
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy
Conditions:
Breast Cancer; Colon Cancer; Bladder Cancer
Interventions:
Drug: Glycosylated Recombinant Human Interleukin-7; Biological: Diphtheria-Tetanus Vaccine; Biological: Polio Vaccine; Biological: Pneumaococcal Vaccine; Biological: Hepatitis A Vaccine; Biological: Hepatitis B Vaccine; Biological: Influenza Vaccine; Biological: PhiX 174
143
Recruiting
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
Conditions:
HIV Coinfection; Hepatitis C; Hepatitis B; Hepatotoxicity
Interventions:
Drug: Maraviroc; Drug: Placebo
144
Recruiting
Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy
Condition:
Hepatitis C
Interventions:
Drug: Silymarin; Drug: Placebo
145
Not yet recruiting
Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial
Conditions:
Type 2 Diabetes; Liver Cirrhosis
Interventions:
Drug: Glargine & Glulisine; Drug: Regular insulin; Drug: NPH & regular insulin
146
Recruiting
Ribavirin, Its Dosing Regime
Condition:
Hepatitis C
Intervention:
Drug: Ribavirin
147
Not yet recruiting
Improved Prevention of Perinatal Hepatitis B Transmission
Condition:
Liver Fibrosis
Intervention:
Biological: Sci B vac
148
Not yet recruiting
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
Conditions:
Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Mantle Cell Lymphoma Recurrent
Interventions:
Procedure: peripheral blood stem cell transplantation (PBSCT); Biological: filgrastim; Genetic: polymerase chain reaction; Biological: rituximab; Biological: genetically engineered lymphocyte therapy; Other: laboratory biomarker analysis; Drug: plerixafor; Procedure: autologous hematopoietic stem cell transplantation
149
Not yet recruiting
Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases
Condition:
Hepatobiliary Diseases
Intervention:
150
Not yet recruiting
Japanese Bridging Study Conducted in the United States
Condition:
Hepatitis C Virus
Interventions:
Drug: BMS-791325; Drug: Placebo
151
Recruiting
Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Conditions:
Hepatocellular Carcinoma; Liver Cancer
Intervention:
Drug: bavituximab and sorafenib
152
Recruiting
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
Condition:
Advanced Hepatocellular Carcinoma (HCC)
Interventions:
Drug: OSI-906; Other: Placebo
153
Recruiting
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Condition:
Hepatitis B Virus
Interventions:
Drug: pegIFN; Drug: pegIFNα-2a
154
Recruiting
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Conditions:
Chronic HIV Infection; HCV Coinfection
Intervention:
Drug: Fosamprenavir
155
Recruiting
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
Condition:
Liver Cancer
Interventions:
Drug: everolimus; Drug: sorafenib tosylate; Other: questionnaire administration; Procedure: computed tomography; Procedure: magnetic resonance imaging; Procedure: quality-of-life assessment
156
Recruiting
Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
Conditions:
Poliomyelitis; Haemophilus Influenzae Type b Disease; Hepatitis B; Diphtheria; Pertussis; Tetanus
Interventions:
Biological: GSK217744; Biological: Infanrix hexa™; Biological: Prevenar 13®
157
Not yet recruiting
Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard Therapy
Condition:
Asymptomatic Chronic HCV Carriers
Intervention:
Drug: Bovine Colostrum Powder
158
Not yet recruiting
Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects
Condition:
Hepatitis C
Interventions:
Drug: Midazolam; Drug: BMS-791325
159
Recruiting
Effects of Motivational Interviewing on Risky Injecting Practices Among Injecting Drug Users (IDUs)
Conditions:
HIV; Hepatitis C
Interventions:
Behavioral: Motivational interviewing; Behavioral: Educational intervention
160
Recruiting
Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
Conditions:
Pediatric Cancers; Multiple Diseases
Interventions:
Biological: Immunization Schedule patients <7 years.; Biological: Immunization Schedule patients > or = to 7 years and <11 years of age; Biological: Immunization Schedule patients > or = to 11 years of age
161
Not yet recruiting
Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants
Conditions:
Cholera; Diarrhea; Vibrio Infections
Interventions:
Biological: Bivalent killed oral cholera vaccine; Biological: Killed Escherichia coli K12 placebo
162
Recruiting
A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006 AM1)
Conditions:
Bacterial Infections; Virus Diseases
Interventions:
Biological: V419; Biological: PENTACEL™; Biological: Prevnar 13™; Biological: RotaTeq™; Biological: Modified process hepatitis B vaccine
163
Not yet recruiting
Fibrinogen as an Alternative to FFP in Aortic Surgery.
Condition:
Coagulopathy in Patients Having Thoraco-Abdominal Aneurysm Repair
Interventions:
Biological: Fibrinogen concentrate; Biological: Fresh Frozen Plasma
164
Recruiting
Trial Comparing Different Ribavirin Dosages and Different Duration of Treatment in Combination With Pegylated Interferon in Patients With Genotype 2 and 3
Condition:
Chronic Hepatitis
Intervention:
Drug: Peginterferon alpha-2a + Ribavirin
165
Recruiting
Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a vs Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Chronic Hepatitis B(CHB).
Condition:
Chronic Hepatitis B
Interventions:
Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate; Drug: Peginterferon α-2a
166
Recruiting
Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B
Condition:
Chronic Hepatitis B
Interventions:
Drug: pegylated interferon a-2a; Drug: Entecavir
167
Not yet recruiting
PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients
Condition:
Chronic Hepatitis B
Interventions:
Drug: Peginterferon alfa-2a; Drug: Nucleos(t)ide analogue
168
Not yet recruiting
Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure
Condition:
Acute on Chronic Hepatic Failure
Interventions:
Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO); Drug: Placebo
169
Recruiting
Modified Dose and Schedule of Recombinant Hepatitis B Vaccination in HIV-infected Adult Subjects
Condition:
HIV Infection
Intervention:
Biological: Hepavax-Gene
170
Recruiting
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
Conditions:
Acquired Immunodeficiency Syndrome; HIV Infections
Interventions:
Drug: emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line); Drug: abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line); Drug: emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
171
Recruiting
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants.
Conditions:
Poliomyelitis; Haemophilus Influenzae Type b Disease; Hepatitis B; Diphtheria; Pertussis; Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis Vaccines; Tetanus
Intervention:
Biological: Infanrix™ hexa
172
Recruiting
Methadone Maintenance & HIV Risk in Ukraine
Condition:
Opioid Dependence
Intervention:
Drug: Methadone
173
Recruiting
Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection
Condition:
Hepatitis B, Chronic
Interventions:
Drug: lamivudine; Drug: Telbivudine; Drug: Enticavir; Drug: Adefovir Dipivoxil Tablets
174
Recruiting
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Condition:
Hepatorenal Syndrome Type 1
Interventions:
Drug: Terlipressin; Drug: Placebo
175
Recruiting
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Conditions:
Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.; Papillomavirus Vaccines
Intervention:
Biological: GSK580299, GSK Biological's HPV vaccine
176
Recruiting
Cohort of Young Adults Infected With HIV Since Birth or During Childhood
Conditions:
HIV Infection; Young Adult
Intervention:
Biological: blood sampling, specific biological exams and biobank and self administered questionnaires
177
Recruiting
Probiotics for Portal Hypertension
Conditions:
Cirrhosis; Varices, Esophageal
Intervention:
Drug: Propranolol, Norfloxacin, VSL#3
No comments:
Post a Comment